Latest filing published 05 Mar 2024 for Sunshine Biopharma, Inc, €9,223.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -98.2%Entry US$1,320.00 · Close at T+365 US$23.40
- -98.2%Entry US$1,380.00 · Close at T+365 US$24.70
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Steve N. Slilaty: trading record in brief
Steve N. Slilaty, listed as chief executive, appears in our data through filings on Sunshine Biopharma, Inc shares, published by SEC (Form 4). The record holds 24 filings, for trades running from 21 December 2011 to 4 March 2024.
Market trades split into 4 purchases (€101k) and 1 sale (€103k). Netting one side against the other leaves €2,499 of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 10 share grants. 2024 to date brings 2 purchases and no sales.
In size, the median ticket on the buying side is €27k. Across 3 purchases, this insider has always bought alone, with no colleague buying within 30 days.
On 5 March 2024 came the latest disclosure, an open-market purchase for €9,223 in Sunshine Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 16 days after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Steve N. Slilaty
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 100,000 shares@ US$0.109.4% of flowSeries B Preferred StockSEC:0001683168-24-001322:0Canonical exit: 2 Jun 2024 (T+90)
- 20,000 shares@ US$0.101.9% of flowSeries B Preferred StockSEC:0001683168-24-000879:0Canonical exit: 8 May 2024 (T+90)
- 990,000 shares@ US$0.1088.7% of flowSeries B Preferred StockSEC:0001683168-22-001185:0
- 20,000,000 shares0Common StockSEC:0001128732-21-000002:0
- 1,100,000 shares0Common StockSEC:0001128732-20-000003:0
- 1,300,000 shares0Common StockSEC:0001128732-20-000003:1
- 323,673 shares0Common StockSEC:0001128732-20-000003:2
- 500,000 shares@ US$0.1031.2% of flowSeries "B" Preferred StockSEC:0001128732-20-000002:0
- 13,000,000 shares0Common StockSEC:0001128732-19-000024:0
- 38,000,000 shares0Common StockSEC:0001128732-18-000011:0
- 27,000,000 shares0Common StockSEC:0001128732-18-000006:0
- 14,000,000 shares0Common StockSEC:0001128732-17-000031:0
- 26,000,000 shares0Common StockSEC:0001128732-16-000036:0
- 136,861,968 shares0Common StockSEC:0001128732-16-000030:0
- 321,305,416 shares0Common StockSEC:0001128732-16-000025:0
- 253,082 shares@ US$0.197616.8% of flowCommon StockSEC:0001128732-16-000018:0Canonical exit: 11 Jul 2016 (T+90)
- 12,000,000 shares@ US$0.00728.5% of flowCommon StockSEC:0001128732-16-000018:1
- 500,000 shares@ US$0.10Series "B" Preferred StockSEC:0001013596-15-000003:0Canonical exit: 25 Aug 2015 (T+90)
- 1,200,000 shares@ US$0.02Common StockSEC:0001128732-15-000001:0
- 150,000 shares@ US$0.02Common StockSEC:0001128732-15-000001:1
- 17,000,000 shares0Common StockSEC:0001013596-12-000009:0
- 2,591,500 shares@ US$0.05Common StockSEC:0001013596-12-000009:1
- 17,000,000 shares0Common StockSEC:0001013596-12-000006:0
- 2,591,500 shares@ US$0.05Common StockSEC:0001013596-12-000006:1
24 of 24 declarations